Mitochondrial Dysfunction in Parkinson's Disease by Keane, P. C. et al.
SAGE-HindawiAccess to Research
Parkinson’s Disease
Volume 2011, Article ID 716871, 18 pages
doi:10.4061/2011/716871
Review Article
MitochondrialDysfunction inParkinson’sDisease
P. C. Keane,1 M. Kurzawa,1,2,3 P. G. Blain,1 andC.M.Morris1,3
1Medical Toxicology Centre, Wolfson Unit, Newcastle University, Claremont Place, Newcastle upon Tyne NE2 4AA, UK
2Institute of Human Genetics, Newcastle University, Central Parkway, Newcastle upon Tyne NE1 4EA, UK
3Institute for Ageing and Health, Newcastle University, Newcastle upon Tyne NE4 6BE, UK
Correspondence should be addressed to P. C. Keane, paul.keane@ncl.ac.uk
Received 1 November 2010; Revised 3 January 2011; Accepted 16 January 2011
Academic Editor: R. H. Swerdlow
Copyright © 2011 P. C. Keane et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Parkinson’s disease (PD) is a progressive, neurodegenerative condition that has increasingly been linked with mitochondrial
dysfunction and inhibition of the electron transport chain. This inhibition leads to the generation of reactive oxygen species
and depletion of cellular energy levels, which can consequently cause cellular damage and death mediated by oxidative stress
and excitotoxicity. A number of genes that have been shown to have links with inherited forms of PD encode mitochondrial
proteins or proteins implicated in mitochondrial dysfunction, supporting the central involvement of mitochondria in PD. This
involvement is corroborated by reports that environmental toxins that inhibit the mitochondrial respiratory chain have been
shownto be associatedwithPD. This paper aimsto illustrate theconsiderable body of evidence linking mitochondrialdysfunction
with neuronal cell death in the substantia nigra pars compacta (SNpc) of PD patients and to highlight the important need for
further research in this area.
1.Introduction
Parkinson’s disease (PD) is a progressive, neurodegenerative
conditioncharacterisedbydeteriorationofthedopaminergic
(DA) neurons of the substantia nigra pars compacta (SNpc)
[1, 2]. The exact mechanism by which SNpc cell death
in PD occurs is poorly understood, but several lines of
evidence implicate mitochondrial dysfunction as a possible
primary cause due to the central role of mitochondria in
energy production, along with oxidative stress, ubiquitin
system impairment and excitotoxicity, all of which may be
interlinked [3–5]. Mitochondrial dysfunction with complex
I deﬁciency and impaired electron transfer in the substantia
nigra in PD have been reported [3, 4]. Moreover, mutations
in several mitochondrial proteins have been associated with
familial forms of PD [5–7], as well as the presence of
deletions in mitochondrial DNA identiﬁed in aging controls
andPDsubstantianigra[8].Thispaperdiscussesthepossible
mechanisms relating mitochondrial impairment tocelldeath
in PD.
2.Mitochondria
Mitochondria are found in virtually all eukaryotic cells and
function to generate cellular energy in the form of adenosine
triphosphate (ATP) by oxidative phosphorylation and are
thought to be derived evolutionarily from the fusion of
prokaryotic and eukaryotic organisms [9, 10]. They are
also involved in regulation of cell death via apoptosis,
calcium homeostasis, haem biosynthesis, and the formation
and export of iron-sulphur (Fe-S) clusters, that have been
reviewed in detail elsewhere [11–13] ,a n df u n c t i o ni nt h e
c o n t r o lo fc e l ld i v i s i o na n dg r o w t h .
Structurally, mitochondria are composed of a double
lipid bilayer with a phospholipid outer membrane and an
inner membrane which surrounds the intracompartmental
matrix (Figure 1). The space between the two membranes is
important in, and contains the major units of, oxidative
phosphorylation [9]. Mitochondria are unique amongst
cellular organelles in that they have their own, circular,
double-stranded, DNA (mtDNA) which is inherited almost2 Parkinson’s Disease
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Figure 1: An electron micrograph to show mitochondrial ultra-
structure. Reproduced withthekindpermissionofTracyDavey,EM
Research Services, Newcastle University.
exclusively down the maternal line and codes for 37 mito-
chondrial genes, 13 of which translate to proteins involved
in oxidative phosphorylation [10, 14]. The remaining genes
encode transfer (22) and ribosomal (2) RNA allowing the
mitochondria to generate their own proteins [10]. Although
mitochondria have the ability to produce proteins, the vast
majority of proteins that function within the mitochondria,
including those involved in DNA transcription, translation,
and repair, are encoded by nuclear DNA and are transported
into the mitochondria from the cytosol [10]. As mtDNA is
locatedinthemitochondriaincloseproximitytotheelectron
transport chain it is more susceptible to damage from free
radicals generated during oxidative phosphorylation [15].
This damage may lead to mutations that have been linked
with PD [13, 16] and will be discussed later.
2.1. Electron Transport Chain. The electron transport chain
is composed of ﬁve complexes including an ATP-synthase
located in the inner mitochondrial membrane. The function
of the chain is to generate cellular energy in the form of ATP.
This is accomplished by the transport of electrons between
complexes causing proton (H+ ions) movement from the
matrix to the intermembrane space generating a proton
concentration gradient used by ATP-synthase to produce
ATP (Figure 2).
Whilst electron transport is a highly eﬃcient process in
mitochondria [17], during the process of oxidative phos-
phorylation, electrons can leak from the chain, speciﬁcally
from CI [18] and CIII [19], and react with oxygen to form
superoxide (·O2
−). Under normal physiological conditions
this ·O2
− production occurs at relatively low levels, with
approximately 1% of the mitochondrial electron ﬂow form-
ing ·O2
− [20],andisremovedbymitochondrial antioxidants
such as manganese superoxide dismutase (MnSOD) which
converts ·O2
− to H2O2 which is then converted to H2Ob y
glutathione (GSH). Given the high activity of the respiratory
chain under even normal circumstances, the small leakage
of electrons in mitochondria is still a major source of
·O2
− within many eukaryotic cells [21]. It is thought that
dysfunction in this process leading to an increase in ·O2
−
production could be one of the main drivers of cell death in
the SNpc in PD [22, 23].
2.2. Electron Transport Chain Dysfunction in PD. As neurons
haveaconsiderableenergyneed andarealso highlyequipped
with mitochondria they are extremely sensitive to mito-
chondrial dysfunction. Several neurological disorders are
associated with mitochondrial dysfunction and demonstrate
enhanced production of free-radical species [16, 24]. The
ﬁrst line of evidence for a link between mitochondrial
dysfunction and PD came from the descriptionofComplex I
(CI) deﬁciency in the postmortem SNpc of PD patients and
has been suggested to be one of the fundamental causes of
PD [4, 25]. This CI deﬁciency was also seen in the frontal
cortex in PD [26], and in peripheral tissues such as platelets
[27] and skeletal muscle [28] suggesting that there is a global
reduction in mitochondrial CI activity in PD. This defect
may be due to oxidative damage to CI and misassembly,
since this is a feature of isolated PD brain mitochondria [3].
Incidental Lewy body disease (ILBD) which is considered by
some to be a preclinical indicator of PD, has been shown
to have an intermediate level of CI activity in the SNpc
betweenhealthyandPDpatients[22]whichfurthersupports
the theory of mitochondrial dysfunction. This inhibition
of CI can lead to the degeneration of aﬀected neurons by
a number of mechanisms such as increased oxidative stress
and excitotoxicity [23] which will be described below.
A decrease in the function of Complex III has also been
reported in the lymphocytes and platelets of PD patients
[27, 29]. A link between impairment of mitochondrial CIII
assembly, an increase in free radical-production, and PD
has also been identiﬁed [30]. This increase in free radical
release may be due to the increased leakage of electrons
from CIII (as explained below). Alternatively the inhibi-
tion of CIII assembly causes a severe reduction in the
levels of functional CI in mitochondria [31] which could
lead to an increase in free-radical production through CI
deﬁciency. In addition, the CI and II electron acceptor
ubiquinone has also shown to be reduced in the mitochon-
dria of PD patients [32] and loss of DA neurons in aged
mice treated with the Parkinsonian neurotoxin 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)was attenuated
byubiquinone[33],providingmoreevidencefortheinvolve-
ment of mitochondrial dysfunction in PD.
3.Mitochondrial GenerationofReactive
OxygenSpeciesinPD
Complex I or III inhibition causes an increase in the release
of electrons from the transport chain into the mitochondrial
matrix which then react with oxygento form reactive oxygen
species (ROS) such as ·O2
−, hydroxyl radicals (·OH) and
nitric oxide (NO·). This increase in the normal electron
leakage occurs by blockage of electron movement along the
chain to the next acceptor molecule. An example of this isParkinson’s Disease 3
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Figure 2: Mitochondrial electron transport chain: schematic representation of the mitochondrial electron transport chain involved in
oxidative phosphorylation. CI and II (Complexes I and II) transport electrons (e−s) generated by the conversion of NADH to NAD+ (CI)
or FADH2 to FAD (CII) through Q (ubiquinone), CIII, Cyt c (cytochrome c) and ﬁnally CIV, which uses an e− to convert O2 to H2O.
During electron transfer, CI, II, and IV pump protons (H+s) from the mitochondrial matrix into the intermembrane space generating a H+
concentration gradient that drives the formationof ATP from ADP by ATP-synthase (Complex V).
the ﬁnding that blockade of the electron accepting capability
of the ubiquinone binding site of Complex I leads to an
increased production of electron radicals in rat skeletal
muscle mitochondria [34]. The ROS formed can act as sig-
nalling molecules by causing lipid peroxidation or promote
excitotoxicity, all leading to modiﬁcation of proteins and
eventual cell death. The main areas in which ROS cause
damage in the cell include oxidative DNA damage, lipid
peroxidation, and protein oxidation and nitration. The ·OH
radical has been shown to react with the double bond of
DNA bases leading to damaging DNA lesions [35]a n da n
impairment of normal cellular function. There is evidence
linking this mechanism of cell death to PD in the ﬁnding of
increased levels of 8-hydroxyguanosine, produced by oxida-
tive damage to DNA, in the SNpc of PD patients [36, 37].
Peroxynitrite (formation discussed below) also increases
DNAsingle-strand breaks[38]whichcauseactivationofpoly
(ADP-ribose) polymerase (PARP) which in turn disrupts
the mitochondrial respiratory chain and ATP production via
depletion of intracellular NAD+ stores, so exacerbating the
original mitochondrial dysfunction [39].
3.1. ROS-Mediated Protein Damage. Amongst the most
common mechanisms of protein damage caused by ROS is
oxidation to form carbonyl groups on proteins and nitration
by peroxynitrite. Reactive ROS can readily oxidise amino
acids on various cellular proteins to form carbonyl groups,
which can disrupt the physiological function of the aﬀected
protein and lead to cytotoxic protein aggregates, activation
of cell death pathways, and impairment of neuroprotective
pathways[40].Anincrease inthesecarbonyl groupshasbeen
reported in the SNpc and in the basal ganglia and prefrontal
cortex of PD patients [41] suggesting a role in the disease
which is widespread throughout the brain. Peroxynitrite
formed by the reaction of ROS with nitric oxide and nitrates
tyrosine residues on proteins [42], damaging them and
leading to cell death. These nitrotyrosine residuesare present
in Lewy bodies in PD neurons signifying the possibility that
protein nitration may contribute to the pathology of PD
[43]. Peroxynitrite [44]a n do t h e rR O S[ 45] can also oxidise
sulphydryl groups on glutathione, leading to depletion of
antioxidant defences, and other thiol containing cofactors
disrupting various cellular processes and structures. The
ﬁnal link between PD and mitochondrially generated ROS
throughproteindamagecomeswith thediscoveryofnitrated
and oxidativelydamaged misfolded proteinsthat have strong
genetic links with the disease such as α-synuclein, DJ-1,
Parkin and PINK1 [46–51] suggesting that these disease-
associated proteins are major targets of free-radical damage
in sporadic forms of PD.
Lipidperoxidationisanotherofthemaintypesofcellular
damage caused by ROS occurring when ROS react with
hydrogen in the lipid leading to the formation of a lipid
radical. This radical can then form a further lipid radical via
an intermediary by reacting with a hydrogen atom leading
to a chain reaction and breakdown of the lipid. In the cell4 Parkinson’s Disease
membrane, phospholipids are particularly susceptible to this
damage due to their polyunsaturated nature, leading to
damage to cell and organelle membranes and severe cellular
dysfunction. There have been strong links between increased
lipid peroxidation and PD with increased levels shown to
be present and cause cell death in the nigral cells of PD
patients [36, 37], suggesting a role for it in the mechanisms
of neuronal death.
All of these mechanisms of oxidative stress can feed back
to the mitochondria via a series of signalling pathways and
cause further exacerbation and mitochondrial dysfunction
by damaging mtDNA. In this way, ROS-driven mitochon-
drial dysfunction acts to propagate itself via a feedback
loop leading to accelerated cellular damage and death and
contributing to PD.
This oxidative damage could be exacerbated in PD by
the discovery of reduced antioxidant defences in patients
with the disease. The main line of evidence regards reduced
GSH, which has been found to be selectively decreased in
the SNpc of patients with PD [52], leading to a decline
in cellular capability to inactivate H2O2 and peroxynitrite.
This is thought to be an early event in PD pathology since
lower levels of reduced GSH in incidental LB disease are
of the same magnitude as those found in PD [53]. There
have not been consistent reports of changes in the levels of
most of the other major antioxidant systems; however, cases
of an increase in mitochondrially located MnSOD in PD
patients have been described [54, 55]. This supports a link
between mitochondrial dysfunction generated superoxide
a n dP Ds i n c eM n S O Di st h em a i n·O2
− scavenging system
in mitochondria.
Since there are elevated markers of oxidative damage
in the brains of PD patients, including lipid peroxidation
[36]p r o t e i nd a m a g e[ 41, 43], and oxidative DNA damage
[36, 37], oxidative stress is an established event in PD.
This evidence combined with the PD-like eﬀects of known
Complex I inhibitors such as MPTP [56] and rotenone [57]
and an increase in the activity of neutralising superoxide
dismutase (SOD), particularly the mitochondrially localised
MnSOD, being found in neurodegenerative disease patients
[58] points to a strong link between ROS, possibly caused by
mitochondrial dysfunction and PD.
3.2. Involvement of Iron in Oxidative Stress. Iron may also
be involved in the production and propagation of oxidative
stress in the mitochondria of DA neurons in PD. Iron
is intrinsically linked with mitochondrial function and
particularly the brain, since iron is an integral component
of all respiratory chain complexes and the uptake of iron by
the brain is linked with mitochondrial energy demands [59].
Increased iron levels in the brain have long been associated
with PD [60–63] although this increase may be an eﬀect of
the normal pathological clearance of iron that occurs during
celldeaththat occurs in PD.Morerecently,a speciﬁc increase
in intracellular iron has been observed in SNpc neurones
in PD patients [46] suggesting an increase in the cellular
accumulation of iron in the disease. Cellular iron normally
enters into neurones via the transferrin receptor system and
evidence suggests that there is a reduction of this system
in PD [64, 65] although this may relate more to the loss
of SNpc neurones in PD [47]. This iron may also be taken
up into the mitochondria in the SNpc via the transferrin
receptor 2 and increased levels of ferritin have been reported
in the mitochondria of SNpc DA neurons of PD patients and
rats treated with rotenone [48]. ROS with a low oxidative
potential, like ·O2
− generated via dysfunction of oxidative
phosphorylation, can increase the release of reactive ferrous
iron from this ferritin so leading to the creation of more
ROS via the Fenton reaction [49] and increasing oxidative
stress and cell damage. The evidence that abnormal iron
homeostasis ispresentinPDisclear;however,theroleofiron
in PD as either an initiator or a consequence of pathology
remains to be elucidated.
4.Involvement of Ca2+ inMitochondrial
Dysfunction andPD
4.1. Excitotoxicity. The cellular damage caused by electron
transfer chain inhibition may contribute to neuronal exci-
totoxicity exacerbating neurotoxicity in PD. Several mech-
anisms for excitotoxicity in neurodegenerative conditions
have been proposed [50, 51]. Excitotoxicity occurs when
depolarisation of the neuronal cell membrane from −90mV
to between −60 and −30mV leads to a decrease in the
magnesium blockade of N-methyl-D-aspartate (NMDA)
receptors. This, in turn, leads to NMDA receptor activation
by latent levels of glutamate and causes an intracellular Ca2+
accumulation. This increase in Ca2+ is then thought to cause
neurotoxicity by two main mechanisms. Firstly, Ca2+ causes
an increase in intracellular NO via activation of nitric oxide
synthase (NOS). The excess of NO in the cell can react
with ·O2
− to form peroxynitrite [66], which can cause cell
death by mechanisms similar to those caused by ROS and
mentioned above. Besides the peroxynitrite, NO itself can
lead to cell damage via nitrosylation of various proteins.
A second mechanism driven by intracellular Ca2+
increase causes toxicity in DA neurons by acting on mito-
chondria themselves. The Ca2+ inﬂux is extensively accu-
mulated in the mitochondria and leads to eﬀects on mito-
chondrial membrane potential and ATP synthesis as well as
generation ofROS[67] contributingto the oxidative damage
discussed above. This also all feeds back causing further
malfunction of the cell’s Ca2+ homeostasis and additional
cellular damage.
Mitochondrial dysfunction can lead to excitotoxicity and
causeareductionincellularATPlevels,anincreaseincellular
Ca2+, or a combination of both [23]. Inhibition of Complex
I,andconsequentlyATPgeneration,lowersintracellularATP,
leadingtopartial neuronaldepolarisation, duetoareduction
in the activity of Na+/K+-ATPase. The Na+/K+-ATPase acts
to maintain the resting membrane potential of the cell.
A reduction in ATP levels will compromise this function
leading to depolarisation and, therefore, excitotoxicity via
over activation of NMDA receptors. Intracellular Ca2+ can
be increased by two methods, that is, either directly by
mitochondrial impairment or by over activity of NMDA
receptors. Mitochondria can take up Ca2+ from the cytosol
via an uniporter transporter or a transient “rapid mode”,Parkinson’s Disease 5
both of which rely on the mitochondrial membrane poten-
tial, reviewed by [68]. The ROS generated by mitochondrial
respiratory chain dysfunction can damage the mitochondrial
membranes and disrupt this mechanism of Ca2+ uptake
and storage, thereby raising intracellular Ca2+ levels and
exacerbating the excitotoxicity. Sherer et al. showed that
this could be a viable mechanism for cell death in PD
by inhibiting Complex I in SH-SY5Y cells and showing
a disruption in the mitochondrial membrane potential
leading to an increased susceptibility to calcium overload
[69]. It has also been shown that there is an increase in
glutamate activity linked to excitotoxicity in the SNpc of
mice treated with the Parkinsonian toxin MPTP, which may
be linked to apoptosis and autophagy [70]. This evidence
suggeststhatmitochondriallyderivedordrivenexcitotoxicity
could be a major contributory factor in PD.
4.2. Nonexcitotoxic Involvement of Ca2+. Further to being
integrally involved in mitochondrially generated excitotoxic
cell death in PD, Ca2+ has been implicated in other
mechanisms of cell death in the disease that may involve
compromise of the role of mitochondria as one of the
major intracellular Ca2+ stores. Sheehan et al. reported that
mitochondria from PD patients showed lower sequestration
of calcium than age-matched controls suggesting a role for
Ca2+ homeostasis dysfunction in PD [71]. This would lead
to higher intracellular Ca2+ levels, which has been shown
to amplify free-radical production [72] and, therefore, an
increase in ROS. An increase in cytosolic Ca2+ due to mito-
chondrial dysfunction has also been suggested to activate
calpains and so raise levels of toxic α-synuclein proposing
another link with PD [73], a discovery supported by the
protective eﬀect of calpain inhibition in an MPTP model of
PD [74].
AroleforCa2+ andmitochondria has alsobeensuggested
in a mechanism of increased susceptibility to cell death
speciﬁc to SNpc DA neurons and, therefore, relevant for PD.
S N p cD An e u r o n sa r ea t y p i c a li nt h eb r a i ni nt h a tt h e yh a v e
self-generated pacemaker activity [75] mediated by Cav1.3,
ara r eL - typ eC a 2+ channel [60]. This activity means that that
the Cav1.3channels are open for a higher proportion of time
than Ca2+ channels in other neurons leading to an increased
ATP usage in the cells to pump Ca2+ across the membrane
up steep concentrationgradients [61]. This elevated need for
ATP would lead to an increase in the activity of the electron
transport chain, therefore increasing ROS production so
exacerbating any mitochondrial dysfunction and making
SNpc DA neurons more prone to cell death.
5.Dopamine Metabolismand Mitochondrial
D y sfun ctioninPD
Dopamine metabolism generated oxidative stress has long
been implicated in PD [40]. However, more recently, it has
been suggested that ROS or reactive quinones produced
by oxidation of dopamine, either spontaneously or by
monoamine oxidase (MAO), may have a inhibitory eﬀect on
the proteins of the mitochondrial respiration chain [76–78].
Khan et al. showed that dopamine inhibits Complexes I and
IV, most probably through the actions of the dopamine-
generated quinones rather than through ROS [62]. MAO-
A is bound to the outer mitochondrial membrane and can
oxidise dopamine to form the metabolite 3,4 dihydrox-
yphenylacetic acid (DOPAC), which can itself, or through
oxidation to quinones, locally inhibit Complexes I and IV
[78, 79] although a contradictory report suggests dopamine
but not DOPAC inhibits the electron transport chain [63].
A recent study has shown that dopamine itself, rather than
any oxidation products can directly inhibit Complex I [80]
however, more work would need to be carried out to conﬁrm
this as there is no corroborating evidence.
These links between mitochondrial dysfunction and
dopamine are supported by reports that the PD neurotoxins
and Complex I inhibitors MPTP and rotenone increase
dopamine oxidationand turnover[64, 65] although whether
this is indirectly due to the ROS generating eﬀects of the
toxinsisnotclear. Thishypothesis couldoﬀeran explanation
as to why DA are more susceptible than other neurons to
toxin or mutation mediated mitochondrial dysfunction PD,
as theyare already undera higherlevelofoxidative stress due
to dopamine metabolism generated electron transfer chain
inhibition.
6.Genetic LinksbetweenMitochondrial
Dysfunction andPD
Studies of families who suﬀer from inherited forms of PD
have identiﬁed a number of genes encoding mitochondrial
proteinsorproteinsimplicatedinmitochondrial dysfunction
[46–51, 81].
6.1. α-Synuclein. The α-synuclein gene encodes a small pro-
teinofthesynucleinfamilythatislocalisedtonerveterminals
althoughthephysiologicalfunctionofα-synuclein isunclear.
The ﬁrst link between α-synuclein and PD came with the
discoveryofmutationsintheα-synucleingeneinPDpatients
[48, 49, 51]. This evidence was supported by the discovery
that aggregates of α-synuclein are the major components
of LBs [82]. Although there are many theories on the
mechanism by which mutant α-synuclein causes neuronal
cell death in PD, it has recently been reported that there
is an association between α-synuclein and mitochondrial
dysfunction [83, 84]. Mutant α-synuclein is targeted to and
accumulates in the inner mitochondrial membrane (IMM)
and can cause Complex I impairment and an increase in
ROS, possibly leading to cell death [85].
6.2. Parkin, PINK1, and DJ-1. Parkin, PTEN-induced puta-
tive kinase 1 (PINK1), and DJ-1 are genes that code
for proteins that are crucially involved in mitochondrial
function and resistance to oxidative stress and have been
linked with PD. The Parkin gene encodes an E3 ubiquitin
ligaseinvolvedintheubiquitin-proteasomalsystem,marking
proteins for degradation by the proteasome. Mutations in
Parkin have been linked to autosomal recessive juvenile
parkinsonism [86]. Parkin has also been shown to interact
withandpromotedegradationofα-synuclein[87];therefore,6 Parkinson’s Disease
a loss of function Parkin mutation could contribute to the
α-synuclein driven cell death mentioned above. It has been
suggested that Parkin may also be involved in mitochondrial
function and protection from mitochondrially generated
ROS. Recent work in Parkin null mice has shown a reduction
in subunits of Complex I and IV and reduced function in the
mitochondrial respiratory chain along with increased oxida-
tive stress in brain tissue [88]. This is supported by reduced
mitochondrial Complex I activity in Parkinsonian patients
with Parkin mutations [89] and the increased age-dependent
or rotenone (a Complex I inhibitory toxin) induced DA
neuronal degeneration and mitochondrial abnormalities in
Parkin mutant drosophila [90]. Moreover, a recently gener-
ated zebraﬁsh model of Parkin deﬁciency showed increased
sensitivity of Parkin mutants to proteotoxic stress with
no manifestation of dopaminergic neuron loss or aﬀected
mitochondrial morphology or function [91].
PTEN-induced putative kinase 1 (PINK1) is a ser-
ine/threonine kinase located in the inner mitochondrial
membrane [92] which functions to protect neurons against
various types of cell stress. Mutations in PINK1 are found
to be associated with a autosomal recessive form of PD
[93]. This pathogenesis may be associated with the loss
of kinase activity as PINK1 is known to protect against
cell death only if the kinase function is intact [94].
Several independent groups reported a role of PINK1 in
mitochondrial integrity by regulating the mitochondrial
ﬁssion machinery [95], which might have an impact on
dopaminergic synapses and contribute to DA neuron degen-
eration [96–98]. Knockdown of PINK1 has been shown
to induce mitochondrial oxidative stress, mitochondrial
fragmentation, and autophagy and dysregulate calcium
homeostasis in SH-SY5Y cells [76, 98]. Moreover, there
is evidence of interplay between PINK1 and Parkin, since
Parkin can reduce mitochondrial dysfunction caused by
down-regulation of PINK1 [77]. Furthermore, it has been
shown recently that both PINK1 and Parkin are involved
in removal of damaged mitochondria. The proposed model
suggests that in response to mitochondrial depolariza-
tion PINK1 accumulates on the mitochondrial membrane
and recruits Parkin to promote mitophagy [78, 79].
Therefore, the pathology of mutant PINK1 and/or Parkin
in Parkinsonism may arise from the inability to remove
dysfunctional mitochondria [99].
The DJ-1 gene encodes a widely expressed protein found
in neurons and glia in all central nervous system (CNS)
regions [100].Bonifati ﬁrst identiﬁedan association between
DJ-1 and autosomal recessive early-onset PD [46, 101],
with numerous further familial mutations in DJ-1 being
identiﬁed [102]. Reports have shown that DJ-1 is present in
mitochondria and protects against oxidative neuronal death
[103],DJ-1deﬁcientmicearemoresusceptibletoMPTP[81]
and DJ-1 knockdown in a neuroblastoma cell line renders
the cellsvulnerable to oxidative stress [104]. Finally, a critical
role for DJ-1 in mitochondrial function is shown by a rescue
eﬀect of DJ-1 on neuronal cell death caused by PINK1 but
not Parkin deletion [83]. Moreover, loss of DJ-1 leads to
mitochondrial fragmentation, impaired dynamics, induced
oxidativestress,andautophagy[84,105].Inconclusion,DJ-1
protein has been observed to have pleiotropic functions (see
[106] for further review), with an antioxidative role to be
the most consistent ﬁnding. This may provide a link to
PD whereby a loss of function mutation of DJ-1 causes an
increase in mitochondrial dysfunction and oxidative damage
leading to nigral neuron cell death.
6.3. Other Nuclear Mutations. Omi/Htra2 is a mitochondri-
ally located stress protective serine protease which has been
linked to neurodegeneration [107, 108] with loss of function
mutations being seen in some PD patients [109]. Although
certain studies report no clear genetic association between
theOmi/HtrA2genesequencevariationsandPD[110],there
is evidence of mitochondrial pathology caused by loss of
the Omi/HtrA2 protein function [111]. Omi/Htra2 has also
been shown to have links with Pink1 in protecting against
oxidative stress [112] and interacting in a prosurvival path-
way [113, 114]. Therefore, mutations in thismitochondrially
targeted gene may predispose cells to damage via oxidative
stress generated from mitochondrial dysfunction.
Leucine-richrepeatkinase2(LRRK2)isalarge(280kDa)
protein with kinase activities. Mutations in LRRK2 were ﬁrst
linked with autosomal dominant PD by Zimprich et al. in
2004 [115] and represents the most signiﬁcant cause of auto-
somal dominant PD. LRRK2 has been shown to be localised
to the outer mitochondrial membrane [116, 117]p r o v i d i n g
an association between mutations in this protein in PD and
mitochondrial function. LRRK2 has also been shown to be
linked with mitochondria by the ﬁnding that Drosophila
with LRRK2 mutations show increased susceptibility to the
Complex I inhibitor and mitochondrial toxin rotenone and
increased protection against DA neuron degeneration by the
mitochondrially protective protein Parkin [118].
Al o s so ff u n c t i o nm u t a t i o ni nt h el y s o s o m a lt y p e5P -
type ATPase, ATP13A2, has been shown to have links with
a hereditary form of autosomal recessive early onset PD
with dementia [119]. Gitler et al. reported that functional
ATP13A2 can protect against α-synuclein overexpression
induced toxicity and that knockdown of ATP13A2, enhances
α-synuclein misfolding in neuronal models of PD [120].
With α-synuclein shown to be toxic to Complex I [85], loss
of function mutations in ATP13A2, and therefore impaired
α-synuclein clearance, could be a link to mitochondrial
dysfunction in PD.
PLA2G6 is a calcium-independent phospholipase A2
linked to infantile neuroaxonal dystrophy [121] and neu-
rodegeneration with brain iron accumulation [101]t h a th a s
recently been implicated in PD [122, 123]. PLA2G6 have
been shown to locate to [124], and have a protective role
against oxidative stress in [125], pancreatic β-cell mito-
chondria providing a possible link between loss of function
mutations in this protein and mitochondrial dysfunction
in PD. How, for example, PLA2G6 regulates iron, a major
mitochondrial cofactor is not clear.
6.4. mtDNA Mutations. Besides nuclear DNA mutations,
there have been links between mtDNA mutations and PD.
Bender et al. [8]a n dK r a y t s b e r ge ta l .[ 126]s h o w e dh i g h
levels of mtDNA deletions in neurons in the SNpc of PDParkinson’s Disease 7
Table 1: Summary of mutations and links to mitochondrial dysfunction and PD.
Mutation Link to mitochondria Links with PD
α-synuclein Targeted to IMM and causes CI inhibition (i) Major component of LBs
(ii) Mutation linked with PD
Parkin Suggested role in mitochondrial function and antioxidant
protection Mutation linked to autosomal recessive juvenile PD
PINK1 Interaction with Parkin Loss of kinase mutation linked to familialPD
DJ-1 (i) Antioxidant present in mitochondria
(ii) Rescues mitochondria from PINK1 deletion Mutation linked with numerous cases of familial PD
Omi/Hrta2 (i) Mitochondrial location
(ii) Interaction with PINK1 Loss of function mutations found in PD patients
LRRK2
(i) Protects against mitochondrial CI toxin rotenone
(ii) Increases Parkin mediated cell protection
(iii) Located in outer mitochondrial membrane
Mutation linked with autosomal dominantPD
ATP13A2 Leads to lysosomaldysfunction and build up of α-synuclein
which is toxic to CI Mutation linked with hereditary form of PD
PLA2G6 (i) Located in mitochondria
(ii) Protect mitochondria against oxidative stress Mutations linked to neurodegeneration and recently PD
TFAM (i) Regulates transcription of mtDNA
(ii) Knockout mouse has respiratory chain deﬁciency
(i) Knockout mouse develops PD phenotype
(ii) Mutations in some variants give increased risk of PD
POLG1 (i) Involved in the synthesis and regulation of mtDNA
(ii) Linked to respiratory chain deﬁciency in PD Mutation linked with PD
suﬀerers. It has been hypothesised that these pathologic
DNA rearrangements are not primary drivers of the disease
but may be caused by oxidative stress generated during
mitochondrial dysfunction, and this may further exacerbate
cellular damage [127]. The mitochondrial transcriptional
factor A (TFAM) regulates transcription of mtDNA and
was linked to PD by the ﬁnding that TFAM knockout
mice (MitoPark mice) had reduced mtDNA expression and
respiratory chain deﬁciency in SNpc DA neurons, which
lead to a Parkinsonian phenotype [128]. Although some
studies showed that TFAM mutations do not signiﬁcantly
increase the risk of PD [129, 130], an investigation into the
inﬂuence of TFAM variants on PD depending on mtDNA
haplogroup found certain variants increased the chances of
developing PD [131], suggesting a possible role for mtDNA,
in some instances, and respiratory chain dysfunction in PD.
Mitochondrial DNA polymerase γ 1( P O L G 1 )i sa ne n z y m e
involved in the synthesis and regulation of mtDNA and has
beenshown tohave linkswithPD, includingreduced activity
of mitochondrial respiratory chain complexes [132, 133].
The involvement of mutations of this protein in PD sug-
gests a role for dysregulation of mtDNA in mitochondrial
dysfunction in the disease. However, whether or not there
is a common hereditary role for POLG1 in PD needs
further study, since a large-scale study does not support this
hypothesis [134]( Table 1).
7.Mitochondria and LewyBodyFormation
The histological hallmark of PD is the presence of proteina-
ceous intraneuronal inclusions termed Lewy bodies (LBs)
along with the presence of Lewy neurites (LNs) within
neuronal dendrites and axons [135, 136]. Dysfunction of
protein metabolism appears to be an important factor in
LB formation and the associated neurodegeneration (see for
further review [137]),butthesigniﬁcance of theseaggregates
is still a subject of debate. It is unclear if LBs are pathogenic
and mechanistically cause neuronal death [138]o rr a t h e r
the actual function of LBs is neuroprotective by sequestering
unwanted, potentially toxic proteins [139–141]. The latter
hypothesis is supported clinically by evidence, particularly
from autosomal recessive juvenile Parkinson’s disease due
to Parkin mutation demonstrating that neurodegeneration
can occur without the presence of LBs in both apparently
sporadic and familial forms of PD [142, 143]. LBs are also
reported in cognitively intact individuals over 65 years [144]
although this may indicate a prodromal phase of PD prior to
clinical presentation.
LBs are typically found in brainstem nuclei and in
limbic and neocortical regions in PD and Dementia with
Lewy bodies patients (DLB), and additionally, they can be
identiﬁed in autonomic ganglia in the periphery [145].
There are two morphological types of LBs: brainstem
(classic) and cortical Lewy bodies. Classic Lewy bodies
are intracytoplasmic eosinophylic inclusions that consist of
a dense core surrounded by a pale halo [135]. They are
spherical in shape however, a recent report of Kanazawa
et al. showed also convoluted LBs and their continuity with
LNs, which may suggest evolution from LNs to LBs [146].
Typically, classic LBs are seen in dopaminergic neurons
of the substantia nigra and noradrenergic neurons of the
locus coeruleus although they were originally described in
neurons of the basal forebrain [147]. Cortical LBs are less
well-deﬁned structures compared to classic LBs and are8 Parkinson’s Disease
without the halo and are predominantly located in limbic
areas of the brain, such as the amygdala, entorhinal, insular,
and cingulate cortices [145]. Ultrastructurally, both classic
and cortical LBs are composed of ﬁlamentous, insoluble
in SDS, material resembling neuroﬁlament [148]. Electron
microscope examination of Lewy bodies demonstrates that
the core contains dense granular material, whereas the outer
halo is composed of radiating ﬁlaments of 7–20nm in
diameter [135]. Staging of severity of the pathology of PD
and DLB based on the distribution of LBs in the brain have
been put forward and are used in the classiﬁcation of the
neuropathology of PD and DLB [149].
Immunohistochemical staining and proteomic analyses
have deciphered the complexities of the molecular com-
position of Lewy bodies and Lewy neurites. α-synuclein
[135,150],ubiquitin[151],and neuroﬁlaments [152]appear
to be the major components, with α-synuclein representing
the most prominent and consistent marker of LB/LN.
More recently triple immunolabeling for these epitopes has
revealed a three-layered internal structure of LBs and LNs
[146]. These primary molecular constituents are stratiﬁed
into concentric layers with ubiquitin staining in the center,
surroundedbyα-synucleinandneuroﬁlamentontheperiph-
ery, which is consistent with previous observations [153].
A large number of mitochondria have been observed
in early-stage LBs [132, 154]. Mitochondrial accumulation
has also been found in nigral Lewy and pale bodies
(possibly precursors of LBs [133]) and cortical LBs but not
in classical LBs in PD and in a mouse 26S proteasomal
knockout model [132]. This may suggest direct involve-
ment of mitochondria in early stages of LB formation.
According to the aggresome-related model of LB forma-
tion, mitochondria may be sequestered to the inclusion
bodies in order to facilitate the removal of unwanted
proteins (see [140] for extensive review). LBs also contain
components of the ubiquitin-proteasome system although
unlike functional aggresomes, they fail to degrade abnor-
mal proteins but sequester them to delay neuronal death
[153].
Proteomic analysis of mitochondrial protein composi-
tion of the substantia nigra of mice treated with MPTP com-
pared to controls showed signiﬁcant changes in numerous
protein expression. Of these proteins, DJ-1 protein levels
were signiﬁcantly increased in the toxin-treated mice and
also colocalised with α-synuclein in LB-like inclusions in the
remaining nigral neurons. Moreover, DJ-1 was present in the
halo of classical LBs in nigral tissue of PD patients [155].
Parkin, PINK1, and Omi/HtrA2 have also been localized to
the LBs in cases with PD [156–159]. These proteins have
been shown to interact and are also involved in proteaso-
mal functions [160, 161]. Thus, there is a potential link
between mitochondrial and proteasomal functions, which
mayinﬂuenceα-synucleinbiology.Theinterplaymayinvolve
oxidative stress and ATP production [161]; however, a wider
impact of these cellular pathologies may be speculated.
In addition, α-synuclein has been shown to aﬀect both
proteasome and mitochondria [162, 163] therefore, a vicious
cycle of mitochondrial and proteasomal dysfunction and α-
synucleinaggregation in LBsmayexist(seeforreview[164]).
8.NeurotoxinsThatLinkMitochondrial
Dysfunction andPD
There is extensive evidence that PD can be caused by neu-
rotoxins, speciﬁcally MPTP [165], rotenone [166], paraquat
[167], diquat [168], and 1-Trichloromethyl-1,2,3,4-tetrahy-
dro-β-carboline (TaClo) [169, 170]. These compounds are
thought to act via various mechanisms, but all by causing
mitochondrial dysfunction.
8.1. MPTP. The ﬁrst toxin that linked mitochondrial Com-
plex I inhibition and PD was MPTP (Figure 3). MPTP is
produced as a byproduct of the synthesis of a meperidine
analogue with heroin-like properties [171]. Langston et al.
described in 1983 that users of meperidine reported striking
Parkinsonian symptoms and related this to the presence of
MPTP [172]. It has also been shown to closely reproduce
the DA degeneration and symptoms of PD in various animal
experimental models [173, 174] and has been the most
widely used toxin in animal models of PD [175]. MPTP
readily crosses the bloodbrain barrierand is convertedtothe
toxic 1-methyl-4-phenyl-2,3-dihydropyridium ion (MPP+)
(Figure 3) by monoamine oxidase B in astrocytes [176]
and is then taken up into DA neurons by DAT seen as
a reduction in MPTP toxicity in DAT deﬁcient mice [177].
MPP+ is taken up into mitochondria via passive transport
due to the large mitochondrial transmembrane gradient
[178], where MPP+ inhibits mitochondrial Complex I [179].
This inhibition of Complex I leads to cell death via energy
deﬁcits [180], free radical and ROS generation [181], and
possibly excitotoxicity [182]. In an MPTP mouse model of
PD, α-synuclein is nitrated [183], providing another link
between MPTP and PD. However, despite all of the evidence
oflinksbetweenMPTPandPD,therearediﬀerencesbetween
MPTP models of PD and idiopathic PD with variations in
disease progression, an acute onset, and the lack of typical
LB formation [184].
8.2. Rotenone. Rotenone(Figure 3) is a widely used pesticide
and naturally occurring neurotoxin that has been found to
havelinkstoPD [166].Rotenoneishighly lipophilicandable
to easily cross the blood brain barrier and enter neuronal
cells and intracellular organelles, such as mitochondria,
without the aid of transporters. Rotenone speciﬁcally blocks
the ubiquinone binding site of Complex I, preventing the
transport ofelectronsfromComplex Itoubiquinoneleading
to the release of free radicals into the mitochondrial matrix
and ROS formation [34]. This evidence that rotenone is
a speciﬁc inhibitor of Complex I, which in turn leads to
ROS production and oxidative stress, can also cause PD-
like behavioural symptoms such as akinesia and rigidity
in rats [185]. Rotenone administration has been shown to
oxidatively modify DJ-1 and cause α-synuclein aggregation,
which are eﬀects linked to PD and localised to the DA
neurons of the SNpc [186]. Betarbet et al. reported LB-like
ubiquitinand α-synuclein containing cytoplasmic inclusions
in the brains of rotenone treated rats [57]. This evidence,
taken together, presents a strong link between rotenone
exposure, mitochondrial dysfunction and PD. However,Parkinson’s Disease 9
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Figure 3: Structures of the PD-linked neurotoxins MPTP/MPP+,Rotenone, Paraquat, Diquat, and TaClo.
there is also evidence to suggest rotenone causes damage to
neurons in the striatum but not SNpc [187], suggesting that
it may not be an entirely accurate model of PD.
8.3. Paraquat and Diquat. Paraquat and diquat are widely
usedherbicidesshown tohavelinkswithPD[167,168].They
are hydrophilic compounds and, therefore, do not readily
cross the blood brain barrier and the mechanism by which
they enter the brain is unclear although uptake by a neutral
amino acid [188] or polyamine [189] transporters has been
suggested. Paraquat and diquat have very similar structures
to MPTP and MPP+ (Figure 3), suggesting a similar toxic
mechanism. However, unlike rotenone and MPP+, paraquat
does not inhibit Complex I and is not taken up by DAT,
suggesting an alternative mechanism of cell death [190].
A toxic mechanism is described where paraquat is reduced
to the paraquat radical by Complex I causing accelerated
lipid peroxidation [191, 192]. An alternative theory whereby
paraquat is reduced to the paraquat radical by Complex
II has also been reported [193]. A ﬁnal hypothesis for
the formation of the paraquat radical is that paraquat is
reduced by NADPH-cytochrome p450 reductase [194]o r
NADPH-cytochromecreductase[195]inthecell.Whichever
complex or enzyme is involved, the paraquat radical can
react with oxygen to form ·O2
− and cause oxidative stress
and mitochondrial dysfunction [192]. This mechanism of
cell death may target the DA neurons speciﬁcally because
of their constant state of oxidative stress leaving them
more vulnerable than other cells. It has also been shown
that paraquat can lead to an increase in both α-synuclein
levels and aggregation [196]. Although the exact mechanism
has yet to be elucidated, mitochondrially derived paraquat
radical, combined with its eﬀects on α-synuclein, indicate
paraquat toxicity as a possible mitochondrially mediated
form of PD. Diquat also generates oxygen radicals in rat
brain microsomes [197]; a discovery that, when coupled
with its similarity in structure and properties with paraquat,
suggests a possible similar role for diquat in mitochondrial
dysfunction in PD.
8.4. TaClo. β-carbolines such as TaClo have structures
similar to that of MPTP (Figure 3)a n dm a yb en e u r o t o x i c10 Parkinson’s Disease
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for DA neurons and lead to a PD-like syndrome [169, 170].
Trichloroethylene (TCE) is an industrial solvent used as
a degreasing agent and in dry cleaning. TCE is a major
environmental contaminant in the air, the water system
and soil, and there is, therefore, exposure at low levels to
various groups in the population. It has been discovered
that TCE can be converted to the β-carboline TaClo in man
[198]. TaClo can cross the blood brain barrier following
intraperitoneal injection in the rat [199]. Rausch et al. found
that micromolar concentrations of TaClo caused up to 50%
cell death in primary C57/B16 mouse DA mesencephalon
cultures [200]. This is supported by in vivo studies showing
a reduction in DA metabolism [201], with a progressive
reduction in locomotion and increase in apomorphine-
induced rotations in behavioural tests [202–204]a n dt h e
discovery of a strong inhibition of mitochondrial Complex
I in vitro [205]. Taken together, these data present a strong
case for the neurotoxic properties of TaClo against DA
neurons. Interestingly, further work showed that N-methyl-
TaClo is a more potent inhibitor of mitochondrial Complex
I and more neurotoxic than TaClo itself [206]. This evidence
suggests that TaClo or another related toxin could cause PD
with mitochondrial dysfunction playing a central role. The
mechanisms of environmental toxin induced neuronal cell
death are summarised in Figure 4.
However, this evidence of mitochondrial Complex I
inhibition leading to neuronal cell death in PD following
toxin exposure requires further investigation following the
ﬁndings of Choi et al. that midbrain neurons without Com-
plex I activity were still susceptible to cell death following
rotenone, MPTP, or paraquat treatment [207]. This suggests
that mitochondrial dysfunction could either be occurring
parallel to another nonmitochondrial cell death mechanism
orasasecondaryeﬀectdrivenbysomeothercellularstressor
damage such astoxicprotein accumulationduetoubiquitin-
proteasome system impairment [208], inﬂammation [209],
or DNA damage [210].
9.Conclusions
This paper demonstrates a considerable body of evidence
linking mitochondrial dysfunction, speciﬁcally respiratory
chain inhibition, with neuronal cell death in the SNpc of PD
patients. Many of the mutations related with PD have been
shown to involve mitochondrial proteins or proteins linked
to mitochondrial dysfunction. Furthermore, neurotoxins
that can cause a PD-like syndrome are strong inhibitors
of the mitochondrial electron transfer chain (see Figure 5).
However, the exact mechanisms of cell death in sporadic
PD are still unclear and it has not been conclusively proved
whether mitochondrial dysfunction is a primary driver of
cellular stress and damage in the disease or a secondary
consequence of another insult.
Further investigation should be carried out into how
genes implicated in PD, such as UCH-L1 [211], as well as
those mentioned in this paper, may aﬀect mitochondrial
function and how mutations in these genes could lead to
mitochondrial defects. Although slightly out of the scope
of this paper, it would also be of interest to explore how
reported crosstalk between mitochondria and endoplasmic
reticulum [212] may be involved in cell death control, the
processing of proteins and Ca2+ homeostasis, and how any
deﬁcits in these systems could impact on PD pathology.
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